Separation of enantiomers on HPLC chiral stationary phases based on human plasma alpha1-acid glycoprotein: effect of sugar moiety on chiral recognition ability.
J Haginaka, H Matsunaga
Index: Enantiomer 5(1) , 37-45, (2000)
Full Text: HTML
Abstract
HPLC chiral stationary phases based on human plasma alpha1-acid glycoprotein (AGP) and partially deglycosylated AGP (pd-AGP) were prepared to investigate the effects of sugar moiety of AGP on chiral discrimination of various solutes. Removal of a sugar moiety of AGP by treatment with N-glycosidase was confirmed by high-performance capillary electrophoresis, reversed-phase HPLC and matrix-assisted laser desorption-time of flight (MALDI-TOF) mass spectrometry. The average molecular weights of AGP and pd-AGP were estimated to be ca. 33,000 and 30,600, respectively, by MALDI-TOF mass spectrometry. Next, AGP and pd-AGP were bound to aminopropyl-silica gels activated with N,N '-disuccinimidylcarbonate. The retentivity+ and enantioselectivity of the neutral, acidic and basic solutes tested on the pd-AGP column were significantly or not significantly larger in most solutes than those on the AGP column. This is ascribable to that by cleavage of a sugar chain(s) by N-glycosidase, pd-AGP could become more hydrophobic than AGP, and/ or that a solute could be easily accessible to the specific and/or non-specific binding sites of pd-AGP. It is interesting that warfarin enantiomers are not resolved on the pd-AGP column, but resolved on the AGP column. A sugar chain(s) of AGP cleaved by N-glycosidase might be involved in the enantioselective binding of warfarin enantiomers.
Related Compounds
Related Articles:
2006-01-01
[J. Pharm. Sci. 95(1) , 97-107, (2006)]
2007-07-06
[J. Org. Chem. 72(14) , 5327-36, (2007)]
Solvent-induced inversion of enantiosflectivity in lipase-catalyzed esterification of 2-phenoxypropionic acids. Ueji S, et al.
[Biotechnol. Lett. 14(3) , 163-8, (1992)]
Lipase-catalyzed production of optically active acids via asymmetric hydrolysis of esters. Cambou B and Klibanov AM.
[Appl. Biochem. Biotechnol. 9(3) , 255-60, (1984)]